Reuters logo
BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer
2017年10月30日 / 上午11点06分 / 20 天前

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

Oct 30 (Reuters) - Merrimack Pharmaceuticals Inc

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

* Merrimack Pharmaceuticals - ‍orphan drug designation by FDA includes eligibility for 7-year period of marketing exclusivity for MM-121 upon approval​

* Merrimack Pharmaceuticals - ‍MM-121 is currently being evaluated in SHERLOC study; top-line data for SHERLOC study is expected in H2 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below